ANI Pharma in deal with Merck for two NDAs
USA-based generic drugmaker ANI Pharmaceuticals (Nasdaq: ANIP) has agreed to acquire the New Drug Applications for purified corticotropin gel and corticotropin-zinc hydroxide from pharma giant Merck & Co (NYSE: MRK) for $75 million in cash and a percentage of future net sales.
ANI estimates that the current annual US market for the products it is acquiring is approximately $1 billion, as evidenced by sales of HP Acthar (repository corticotropin injection) gel marketed by Mallinckrodt Pharmaceuticals (NYSE: MNK). The acquisition is being funded through cash on hand and is subject to certain customary closing conditions.
Products approved for multiple disease states
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze